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Abstract The human HADH gene encodes the short-chain-
L-3-hydroxyacyl-CoA dehydrogenase, the enzyme which
catalyzes the third step of the b-oxidation of the fatty acids
in the mitochondrial matrix. Loss-of-function mutations in
the HADH gene lead to short-chain-L-3-hydroxyacyl-CoA
dehydrogenase deficiency, an autosomal recessive genetic
defect of unknown prevalence with a wide spectrum of
phenotypic variability. As in other metabolic diseases, the
diagnostic relevance of the biochemical evaluations, plasma
acylcarnitines, and urinary organic acids, are crucially
dependent on the clinical conditions of the patient during
specimen collection.
This paper describes the eighth patient carrying a HADH
gene mutation, a new homozygous deletion c.565delG
leading to an early stop codon (p.V116Wfs124X), in an
infant with hyperinsulininemic hypoglycemia, displaying
abnormal patterns of plasma acylcarnitines and urinary
organic acids. We conclude that, when the residual catalytic
activity of the mutated enzyme is seriously reduced, the
biochemical hallmarks of the disease, namely plasma
3-hydroxybutyrylcarnitine and urinary 3-hydroxyglutaric
acid, are invariably present.
Introduction
The short-chain-L-3-hydroxyacyl-CoA dehydrogenase (EC
1.1.1.35) is an intramitochondrial homodimer enzyme,
catalyzing the third of the four steps of the b-oxidation of
the fatty acids, namely the NAD+-dependent dehydrogena-
tion of the L-3-hydroxyacyl-CoA to the corresponding
3-ketoacyl-CoA. It is encoded by the HADH gene, mapped
on human chromosome 4q22–q26 (Vredendaal et al. 1996).
Loss-of-function mutations in the HADH gene lead
to short-chain-L-3-hydroxyacyl-CoA dehydrogenase defi-
ciency (Clayton et al. 2001), an autosomal recessive defect
of the b-oxidation of fatty acids, the process providing
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energy during time of fasting, severe febrile illness or
increased muscular activity (Roe and Ding 2001).
The first reported mutations in the HADH gene
referred to a compound heterozygous patient affected
by short-chain-L-3-hydroxyacyl-CoA dehydrogenase
deficiency who presented at 3 years with fulminant hepatic
failure, requiring prompt liver transplant (O’Brien et al.
2000).
Among subjects carrying a mutated HADH gene and
affected by short-chain-L-3-hydroxyacyl-CoA dehydroge-
nase deficiency, a first group of three patients, with residual
enzymatic activity less than 10% of controls, was reported
as having a common feature of hyperinsulinemic hypoke-
totic hypoglycemia (Clayton et al. 2001; Molven et al.
2004; Hussain et al. 2005). The increased plasma level
of 3-hydroxybutyryl-carnitine and the presence of
3-hydroxyglutaric acid in urine were considered informa-
tive biochemical hallmarks of the disease. 3-Hydroxybu-
tyryl-carnitine, belonging stereochemically to the
L-configuration, accumulates because of the defective fatty
acid metabolism, on the contrary, the D-form would suggest
a ketone body utilization defect. The latter could be due
to the impairment of a minor pathway of degradation
of the aminoacids lysine and tryptophan, in which the
short-chain-L-3-hydroxyacyl-CoA dehydrogenase would
catalyze the conversion of the 3-hydroxyglutaryl-CoA to
3-ketoglutaryl-CoA (Molven et al. 2004).
In all these patients, improvement of glucose homeosta-
sis was obtained with diazoxide. The molecular action of
the diazoxide involves opening of the ATP-sensitive
potassium channels (KATP channels), with decreased insulin
secretion. As the matter of fact, the physiological insulin
secretion in the pancreatic b-cells is caused by an increase
in ATP:ADP ratio, which leads to closure of the KATP
channels, resulting in depolarization of the membrane,
influx of calcium and ultimately insulin release (Palladino
et al. 2008). The clinical observation of prompt glucose
homeostasis improvement after diazoxide administration
in these patients has led to the hypothesis that functional
KATP channels were present. Therefore, mutations in the
ABCC8 and KCNJ11 genes, encoding two subunits of the
KATP channels, responsible of most cases, either recessive
or dominant, of congenital hyperinsulinism (Tornovsky
et al. 2004), were excluded.
Congenital hyperinsulinism, characterized by the dysre-
gulated secretion of insulin from pancreatic b-cells (Stanley
1997) is a major cause of persistent hypoglycemia in the
neonatal and infancy period. The genetic basis involves
defects in key genes regulating insulin secretion such as
the above-mentioned ABCC8 and KCNJ11. In addition,
several other dominant forms are due to activating
mutations in GLUD1 (encoding glutamate dehydrogenase
type I) (Stanley et al. 1998), GCK (glucokinase)
(Glaser et al. 1998), HNF4A (hepatocyte nuclear factor
4a) (Kapoor et al. 2008) and SLC16A1 (monocarboxylate
transporter 1) (Otonkoski et al. 2007). Recessive forms
are ascribed to mutations in HADH (Clayton et al. 2001),
with similar prevalence to congenital hyperinsulinism
attributable to HNF4A or GLUD1 (Flanagan et al. 2011).
A functional genomics approach (Hardy et al. 2007) and
a study of the effects of siRNA-mediated HADH silencing
(Martens et al. 2007) led to the conclusion that in case
of short-chain-L-3-hydroxyacyl-CoA dehydrogenase defi-
ciency, the mutation in the HADH gene is actually the cause
of hyperinsulinism.
In a second group of two patients, carrying mutations in
the HADH gene with residual enzymatic activity in the
35–50% of the control range, the plasma acylcarnitine
and the urinary organic acid profiles were either completely
normal (Kapoor et al. 2009), or remarkable for increased
plasma C4-carnitine and urinary glutaric acid (but not
3-hydroxyglutaric acid) (Bennett et al. 2006). In the former
case, the hyperinsulinemic hypoglycemia was triggered by
dietary protein load, whereas in the latter case, the patient
was never hypoglycemic, but presented at 10 months of age
with hepatomegaly and coagulopathy.
One last patient, carrying a homozygous nonsense muta-
tion in the HADH gene, first hospitalized at 2 months of age
for hypoketotic hyperinsulinemic hypoglycemia, displayed
normal plasma acylcarnitine and urinary organic acid profiles,
but, upon reevaluation at 7 years of age, he developed
elevated levels of urinary 3-hydroxybutyric acid, and slightly
increased dicarboxylic aciduria (Di Candia et al. 2009).
Still too few cases are reported in literature to clearly
define the clinical and biochemical spectrum of the disease,
which is likely influenced both by the residual catalytic
activity of the short-chain-L-3-hydroxyacyl-CoA dehydroge-
nase and the environmental conditions. In particular, the
plasma acylcarnitine and the urinary organic acid profiles are
informative only in few cases, likely under acute conditions.
In this report, we describe a patient affected by short-
chain-L-3-hydroxyacyl-CoA dehydrogenase deficiency,
carrying a severe mutation in the HADH gene. The homo-
zygous deletion of one base pair leads to the formation of
an early stop codon within exon 3, in the NAD+-binding
domain of the enzyme. The nonsense mutation located
at the beginning of the mRNA leads to the prediction of
complete absence of the protein. The clinical and biochem-
ical presentation is consistent with hyperinsulinemic hypo-
ketotic hypoglycemia, with informative plasma
acylcarnitines and urinary organic acids.
Case Report
The patient was born in Morocco from consanguineous
Moroccan parents. In the maternal family, two cases of
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neonatal death of unknown causes are reported. The pattern
of transmission of the disease is consistent with an
autosomal recessive inheritance (see Fig. 1).
He was born full-term after an uneventful gestation.
Maternal anamnesis was negative for gestational diabetes.
He was breast-fed till the last day before hospital admission,
when he was also bottle-fed because of breast-milk paucity.
At 3 months of age, he started to show signs of seizures
with hypertonia, staring gaze, cyanosis, and frothing at
the mouth. The seizures were described by the parents as
multiple in a single day, however slight, and spontaneously
resolving in a few seconds.
When the baby was brought to the emergency room, he
was having seizures and was hypoglycemic (blood glucose
1.3 mmol/L), with no detectable ketonuria. Other bio-
chemical routine tests were in the normal range for age.
EEG showed no alteration of electrical activity and cerebral
ultrasound scan excluded congenital malformations. The
baby received an intravenous glucose infusion, in addition
to enteral feed, to maintain normoglycemia (6 mg/kg/min to
maintain plasma glucose between 2.6 and 3.0 mmol/L)
(Aynsley-Green et al. 2000). During the subsequent days
of hospitalization, hypoglycemia occurred whenever
a reduction in the glucose infusion rate was attempted:
sometimes after a few hour-fast, sometimes in the first 2 h
after a meal.
In Table 1, the results of plasma insulin, C-peptide,
ammonia, lactate and blood ketone bodies when the patient
was hypoglycemic are reported. GH, IGF-1, ACTH,
cortisol, and thyroid hormones were all in the reference
ranges. After glucagon injection (0.1 mg/kg), an appro-
priate raise in glucose plasma concentration was obtained.
On the basis of persistent hyperinsulinemic hypoglyce-
mia without evidence of ketosis or metabolic acidosis, we
collected capillary blood spots during fasting hypoglycemia
to perform acylcarnitine analysis.
Therapy with diazoxide at 5 mg/kg/day was instituted,
obtaining prompt clinical response with maintenance of
normoglycemia with usual enteral feeding, without the need
of intravenous glucose infusion.
Fig. 1 Pedigree and details of the HADH sequences of the patient’s
family. Half-filled symbols denote heterozygous carrier subjects.
Filled symbol represents the homozygous propositus. Automated
direct sequencing of PCR amplified genomic DNA of the propositus
and his parents evidenced the deletion c.565delG within exon 3 of the
NAD+-binding domain of the enzyme
Table 1 Patient’s biochemical evaluations corresponding to four different specimen collections. Reference values are reported in italics between
square brackets (bold types refer to pathological or inappropriate values)
Analyte Sample 1 Sample 2 Sample 3 Sample 4
Patient’s age, months+days,(time of withdrawal) 3+18 4+10(9:30 am) 4+10(6:40 pm) 4+17
Plasma glucose (mmol/L) [3.3–5.6] 2.1 2.5 2.7 2.3
Serum insulin (mU/L) [4.0–24.0] <2.0 4.7 22 16
Serum C-peptide (ng/mL) [0.90–7.19] 0.97 NA NA NA
Plasma ammonia (mmol/L) [13.0–42.0] 84 44 56 NA
Plasma lactate (mmol/L) [0.5–2.2] 1.5 NA NA 2
Capillary blood D-3-OH-butyrate (mmol/L) [<0.6] 0.2 0.2 0.2 0.0
NA not analyzed
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The parents denied consent for biopsy and for any
further investigation; therefore, no evaluations of transcrip-
tion and enzymatic activity were carried out.
Materials and Methods
Biochemical Evaluation
For analysis of acylcarnitine and aminoacid profiles,
a 3 mm punch of blood spot sample was first processed
using a NeoBase Non-derivatized MSMS Kit (PerkinElmer
Wallac Oy) and analyzed by multiple reaction monitoring
(MRM) in a tandem mass spectrometer TQD Detector
(Waters), equipped with an ESI source positively charged.
Unlike the derivatized procedure, the nonderivatized
assay cannot distinguish between the two isomers malo-
nylcarnitine (C3DC) and 3-hydroxy-butyrylcarnitine
(C4OH), the latter being the hallmark of the short-
chain-L-3-hydroxyacyl-CoA dehydrogenase deficiency.
Upon detection of an increase in the corresponding mass
transition, in order to evidence which of the two analytes
was actually increased (De Jesús et al. 2010), a derivatized
procedure was also carried out (Turgeon et al. 2008).
Organic acid profile in urine was obtained according
to the conventional method as previously reported (Rinaldo
2008).
HADH Sequencing
Genomic DNA was extracted from peripheral leukocytes
using QIAamp DNA Mini Kit (QIAGEN). The eight exons
of the HADH gene were amplified individually by PCR
using intronic primers (Clayton et al. 2001). The amplicons
were purified using the Exosap-IT clean up Kit (USB)
and then submitted to sequence in both directions
(GenomeLabTM Dye Terminator Cycle Sequencing with
Quick Start Kit, Beckman Coulter). The sequencing
reactions were analyzed on a CEQTM 8800 capillary
sequencer (Beckman Coulter) and results were compared
with the NCBI Reference Sequences NC_000004.11 and
NM_001184705.2.
Results
Biochemical Findings
During hypoglycemia, two blood spots were collected and
acylcarnitines’ analyses were undertaken (see Table 2),
displaying persistently elevated levels of 3-hydroxybutyryl-
carnitine (>0.94 mmol/L). Slightly abnormal values of
some aminoacids were detected as well, but they are likely
due to the metabolic decompensation and hence without
diagnostic relevance.
Urine organic acid analysis performed for diagnostic
confirmation at time of fasting, evidenced increased
quantities of 3-hydroxyglutaric acid (see Fig. 2).
Mutational Analysis
Direct sequencing of the patient’s HADH gene revealed
a new homozygous deletion, c.565delG (reference sequence
NM_001184705.2), located within exon 3 in the NAD+-
binding domain of the enzyme (Fig. 1). The deletion leads
to an inserted frame-shift sequence of eight aminoacids
(WWKPSWRI), followed by the formation of a stop at
codon 124.
The early upstream location along the gene of a stop
codon leads to the reasonable conclusion that a complete
nonfunctional enzyme is produced. The possible presence
of the transcript was not investigated due to the parent
refusal to biopsy and to any further investigation.
Table 2 Patient’s blood spot acylcarnitines’ analysis. Two blood spots, collected during hypoglycemia, were tested with two procedures
(derivatized and nonderivatized) in different laboratories
Analyte Procedure Sample 1 Sample 2 Sample 3
Patient’s age, months+ days,(time of withdrawal) 3+18(9:00 am) 3+18(6:45 pm) 4+17
Plasma glucose (mmol/L) [3.3–5.6] 2.1 2.5 2.3
C4-OH (mmol/L) Derivatized 0.94 NA 1.72
Nonderivatized (isomers: C4-OH + C3DC)a 2.39 1.99 NA
C0 (mmol/L) Derivatized 43 NA 51
Nonderivatized 37 43 NA
C4-OH 3-hydroxybutyrylcarnitine, C3DC malonylcarnitine, C0 free carnitine, NA not analyzed
aWhen the patient’s blood spots were assayed, the internal standard for the determination of the isomers (C4-OH + C3DC) of the NeoBase
Non-derivatized MSMS kit by PerkinElmer was the 2 H6-C5DC. A more recent version of the kit uses for the determination of the same analytes
the internal standard 2 H3-C4
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Both the parents are heterozygous carriers of the same
deletion (Fig. 1).
Discussion
In this paper, we present the eighth case reported in
literature of short-chain-L-3-hydroxyacyl-CoA dehydroge-
nase deficiency with mutation in the HADH gene. At
3 months of age, the patient required hospitalization for
severe hypoglycemia, with the need of a glucose infusion
rate of at least 6 mg/kg/min to maintain normoglycemia.
Hypoglycemia always occurred in the absence of ketone-
mia or acidosis. Plasma insulin concentration, measured
several times during hypoglycemia, was often inappropri-
ately elevated for the glycemia. GH, IGF-1, ACTH,
cortisol, and thyroid hormones concentration were in the
normal ranges, excluding congenital pituitary hormones
deficiency. The mobilization of hepatic glycogen deposits
was not impaired, given the normal glycemic response
to glucagon injection. During hypoglycemia, ammonia
plasma concentration was slightly above the normal range,
but never reached levels suggestive of hyperinsulinemia-
hyperammonemia syndrome (Stanley et al. 1998). Accord-
ingly, a leucine-sensitivity test was not performed.
The blood spot acylcarnitine profile showed consistently
increased concentration of 3-hydroxybutyryl-carnitine,
urinary excretion of 3-hydroxyglutaric acid was also
elevated. Given the suggestive combination of results, we
resolved to investigate the HADH gene of the patient, and
a new homozygous deletion, c.565delG, was identified in
exon 3. The mutation leads to the formation of an early stop
codon, within the NAD+-binding domain of the enzyme.
The actual presence of the mRNA and the residual catalytic
activity were not assessed due to parent refusal to perform
a skin biopsy or any further evaluation as soon as the
diagnosis was established. Nevertheless, on the basis of
the early location along the gene of the stop codon, it is
reasonable to conclude that the corresponding enzyme is
virtually absent.
The molecular mechanism of how defects in HADH
gene lead to unregulated insulin secretion remains unclear.
A recent study identified a high expression of HADH
and a low expression of other b-oxidation enzymes in rat
pancreatic b-cells (Martens et al. 2007). In addition, in the
same cells of the mouse, the short-chain-L-3-hydroxyacyl-
CoA dehydrogenase proved to be a negative regulator of
insulin secretion through a mechanism independent of KATP
channel, suggesting a molecular explanation for the
diazoxide responsiveness of the hyperinsulinemic hypogly-
cemia in patients affected by short-chain-L-3-hydroxyacyl-
CoA dehydrogenase deficiency (Hardy et al. 2007).
Particularly relevant in this view is the in vitro observation
that in human liver mitochondrial extracts, the short-
chain-L-3-hydroxyacyl-CoA dehydrogenase specifically
interacts with glutamate dehydrogenase type I (GLUD1),
known to play an important role in the amino acid induced
insulin secretion (Filling et al. 2008). Further studies on
the molecular interaction between the two proteins in short-
chain-L-3-hydroxyacyl-CoA dehydrogenase deficiency
Time (min)
2
3
IS
4
1
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Fig. 2 Total-ion chromatogram of the trimethylsilyl derivatives of
organic acids extracted from urine of the patient. Panel a: Diagnostic
peak of 3-hydroxyglutaric acid is indicated with an arrow. For
orientation, additional peaks without diagnostic significance are
labeled as follows: (1) lactic acid; (2) urea; (3) succinic acid; (4)
hippuric acid; (IS) tropic acid (internal standard). Panel b: Mass
spectra of 3-hydroxyglutaric acid
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affected patients could partially explain the unpredictable
and intermittent nature of the hyperinsulinemia (Clayton
et al. 2001; Hussain et al. 2005), sometimes triggered by
a protein dietary load (Kapoor et al. 2009), sometimes even
absent (Bennett et al. 2006). Notably, in the hadh knockout
mouse, an animal model of the hyperinsulinemic hypogly-
cemia reported in children with recessive inactivating
mutation of the HADH gene, the insulin secretion dysregu-
lation is due to the loss of an inhibitory protein–protein
interaction of the short-chain-L-3-hydroxyacyl-CoA dehy-
drogenase upon glutamate dehydrogenase (Li et al. 2010).
The diagnostic relevance of the biochemical evaluations,
plasma acylcarnitines, and urinary organic acids is known
to be crucially dependent on the clinical conditions of
the patient during specimen collection. However, when the
residual catalytic activity of the mutated enzyme is
seriously reduced, the hallmarks of the disease, namely
plasma 3-hydroxybutyrylcarnitine and urinary 3-hydroxy-
glutaric acid, are present in all reported cases.
In conclusion, we have described the eighth case
of short-chain-L-3-hydroxyacyl-CoA dehydrogenase
deficiency, with a homozygous deletion in the HADH
gene leading to an early stop codon, characterized by
hyperinsulinemic hypoketotic hypoglycemia with enhanced
3-hydroxybutyryl-carnitine in plasma and 3-hydroxyglutaric
acid in urine.
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